THOMSON REUTERS
CORTELLIS™

# Xencor Inc

## COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 15-Dec-2014

**THOMSON REUTERS**
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents



THOMSON REUTERS

# ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

# GLOSSARY

**Number of Drugs in Active Development**

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Number of Inactive Drugs**

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

**Number of Patents as Owner**

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

**Number of Patents as Third Party**

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

**Patents summary table**

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

**Number of Deals**

A count of deals where the company or one of its subsidiaries is the primary company.

**Key Indications**

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Key Target-based Actions**

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

**Key Technologies**

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

Return to Table of Contents

## TABLE OF CONTENTS


Company Overview..... 7
Company Profile..... 7
Product Portfolio Summary..... 9
Product Portfolio Drugs..... 14


Return to Table of Contents





# Xencor Inc

## COMPANY OVERVIEW

| | |
|---|---|
| **Company Name** | Xencor Inc |
| **Parent Company Name** | Xencor Inc |
| **Website** | http://www.xencor.com/ |
| **Country** | US |
| **Number of Drugs in Active Development** | 11 |
| **Number of Inactive Drugs** | 15 |
| **Number of Patents as Owner** | 66 |
| **Number of Patents as Third Party** | 1 |
| **Number of Deals** | 26 |
| **Key Indications** | Cancer,Autoimmune disease,Rheumatoid arthritis,Systemic lupus erythematosus,Allergy,Asthma,Acute myelogenous leukemia,B-cell lymphoma,Solid tumor,Infectious disease,Inflammatory disease |
| **Key Target-based Actions** | B-lymphocyte antigen CD19 inhibitor,B-lymphocyte antigen CD20 modulator,TNF antagonist,Immunoglobulin gamma Fc receptor IIB antagonist,TNF alpha ligand inhibitor,Immunoglobulin E antagonist,VEGF ligand inhibitor,ADP ribosyl cyclase-1 modulator,Bone marrow stromal antigen 2 modulator,CD30 antagonist,CD40 ligand inhibitor,CD80 antagonist,CD86 antagonist,CDw123 modulator,Cytotoxic T-lymphocyte protein-4 stimulator,EpCAM inhibitor,Epidermal growth factor ligand inhibitor,Erbb2 tyrosine kinase receptor modulator,Folate receptor alpha antagonist,Immunoglobulin gamma Fc receptor IIB modulator,Osteoclast differentiation factor ligand inhibitor,T-cell surface glycoprotein CD5 |
| **Key Technologies** | Biological therapeutic,Parenteral formulation unspecified,Monoclonal antibody humanized,Protein recombinant,Monoclonal antibody,Multivalent antibody,Small molecule therapeutic,Peptide,Monoclonal antibody human,Chimeric monoclonal antibody,Infusion |

## COMPANY PROFILE

### SUMMARY

Xencor Inc is a privately held biotechnology company founded in October 1997 by Stephen Mayo and Bassil Dahiyat with $5 million in venture capital. It was set up to create, develop and commercialize designed proteins as biotechnology products and research tools for the human therapeutic, high throughput screening assay and industrial enzyme markets. Xencor's proprietary tools are ProCode and Protein Design Automation (PDA). ProCode allows the simultaneous analysis of the entire proteome of a cell by creating protein expression libraries where each protein is covalently linked to its corresponding cDNA.

### TECHNOLOGY

Xmab  technology is the company's proprietary platform to produce a portfolio of drug candidates from an antibody with high selectivity for a target antigen by enhancing the antibody-dependent cell cytotoxicity.

### LICENSING AGREEMENTS

In November 2009, Centocor Research & Development to use Xencor's XmAb and Xtend technologies to optimize its antibody drug candidates. Xencor was to receive an upfront payment and was eligible to receive milestones and royalties on product commercialization.

In March 2009, Xencor granted Merck & Co an exclusive license to its Xtend technology for the development of antibodies towards an undisclosed Merck drug target. Xencor would receive an upfront license fee of $3 million, a payment on selection of an Xtend variant, milestone payments and royalties.

In March 2009, Xencor signed an agreement with Pfizer to optimize the performance of therapeutic monoclonal

Return to Table of Contents

antibodies.

In February 2009, Xencor licensed access to its XmAb technology to CSL, for use in advancing the antibody-dependent cell cytotoxicity (ADCC) effector function of CSL's own therapeutic antibodies.The initial phase of the alliance would allow CSL broad access to the technology, to apply towards its complete antibody portfolio. CSL also had commercial licenses in place for the advanced development and commercialization of any antibodies incorporating XmAb; Xencor would receive an upfront payment, plus milestone and royalty payments on each of these antibodies.

In February 2008, Xencor agreed to use its XmAb technology to optimize Human Genome Sciences's monoclonal antibodies against selected targets. Xencor would receive an upfront payment, and was eligible to receive additional milestone payments and royalties on any resulting products that Human Genome commercializes.

In February 2007, Xencor agreed to use its XmAb technology to optimize Boehringer Ingelheim's monoclonal antibodies against selected targets. Xencor would receive an upfront payment, and was eligible to receive additional licence fees, milestones and a royalty payment on any resulting products that Boehringer commercializes.

In February 2006, Xencor granted Centocor a non-exclusive multiyear license to use its ImmunoFilter technology to evaluate the potential immunogenicity of therapeutic proteins, in return for annual license fees.

In January 2006, Xencor granted Eli Lilly a non-exclusive, multiyear license to use its ImmunoFilter technology to evaluate the immunogenicity risk of Lilly's therapeutic proteins.

In December 2005, Xencor gained an exclusive license to technology developed at Cambridge University for making monoclonal antibodies with greatly enhanced potency. The technology included specific Fc variants that complement Xencor's XmAb engineered Fc domains, which could be inserted into antibody candidates against any antigen and may improve effector functions such as enhanced antibody-mediated tumor cell killing, sustained half-life and increased structural stability.

In December 2005, Xencor licensed its XmAb engineered Fc domains to MedImmune for use in the creation of monoclonal antibodies against preclinical tumor targets. Xencor received an upfront payment, as well as license fees, milestones and royalties.

In July 2005, Xencor and Centocor agreed to codevelop monoclonal antibodies with improved anticancer efficacy. Xencor would use its XmAb engineered antibody Fc domains to create drug candidates; Centocor would evaluate these against an oncology target. Xencor was to receive an upfront payment, license fees, and milestone and royalty payments.

In April 2005, Lilly exercised its option to develop one or more therapeutic proteins created by Xencor, which would receive an upfront license fee, milestone payments and royalties. In February 2004, Xencor and Lilly entered a collaboration to optimize the physical and biochemical properties of a protein therapeutic. Xencor would use its PDA technology to create variants of the protein to meet criteria for clinical development. Lilly would have the option to develop the resulting candidates.

In January 2005, Xencor and Roche Holding AG signed a collaboration agreement to use Xencor's XmAb with Roche's antibodies against a cancer target. Xencor would receive technology access and license fees, and future license fees, milestones and royalties if Roche advanced candidates into development; in January 2006, the companies extended the collaboration, allowing Roche to further its research efforts to enhance the therapeutic efficacy of an antibody against a cancer target. Xencor would receive additional fees for the extension.

In January 2005, Xencor and Chugai Pharmaceutical Co Ltd formed a collaboration to use Xencor's XmAb in combination with Chugai's antibodies against a cancer target. Xencor would receive technology access, license fees, milestones and royalties.

In December 2004, Xencor Inc and Genentech entered a collaboration to create next-generation therapeutic antibodies for cancer and autoimmune diseases. Xencor would grant Genentech an exclusive, worldwide license to use its XmAb technology, a suite of engineered antibody Fc domains that can be incorporated into therapeutic candidates, to develop and commercialize products directed against CD20, Her2 and a third undisclosed antigen. In return, Xencor would receive a $5 million upfront fee, annual licensing fees and milestone payments.

In January 2004, Xencor and Protein Design Labs (PDL) entered into an agreement to generate monoclonal antibodies with enhanced potency. The multiyear collaboration allowed PDL to apply Xencor's XmAb technology to a number of preclinical antibodies against various targets. Xencor was to receive technology access and license fees, development milestone payments and royalties. PDL would be responsible for development and commercialization of the resulting products.

In September 2003, Chromos Molecular Systems Inc and Xencor entered into a non-exclusive research license agreement to develop cell lines that expressed Xencor's monoclonal antibodies and other recombinant protein product candidates. Chromos would receive an upfront payment and annual maintenance fees.

Return to Table of Contents

In October 2003, it was reported that Xencor was anticipating partnering a number of its technologies, whilst continuing to develop a number of inhouse projects.

Xencor has ongoing collaborations with the California Institute of Technology (Caltech) and the Massachusetts Institute of Technology (MIT).

## IP NEWS

In January 2008, Xencor announced that the USPTO had granted US-7317091B1 (WO-03074679 and WO-2004029207) which covered its protein design automation technology. The issuance was the first from a series of applications covering Xencor's XmAb antibody Fc engineering technology.

In September 2003, Xencor was issued US-06627186, covering nucleic acids and protein variants of G-CSF with granulopoietic activity'.

## FINANCIAL

In October 2013, Xencor filed a registration statement for an IPO of shares and applied for listing on the NASDAQ stock market under the symbol 'XNCR'. In December 2013, Xencor priced its IPO of 12,730,000 shares of its common stock at a public offering price of $5.50 each. The underwriters were granted a 30-day option to purchase up to an additional 1,909,500 shares of common stock. The shares began trading on the NASDAQ global market under the symbol 'XNCR'. At that time, the offering was expected to close on December 6, 2013. Later that month, the offering was closed; at that time, gross proceeds of approximately $72.5 million were raised by the company.

In October 2007, the company raised an additional $15 million in extended series E financing, bringing the total raised to $60 million.

In October 2006, Xencor raised $45 million from a private financing. The funds included a $6 million bridge financing that was announced in July 2006. Xencor would use the proceeds for the clinical development of two biologics; XPro1595 was to enter the clinic in 2006 for inflammation, and XmAb-2513 was to begin clinical trials for Hodgkin's disease in 2007.

In July 2006, Xencor raised $6 million in a bridge financing led by Novo Nordisk, which committed to invest a further $6 million in future financings.

By October 2005, Xencor had raised $20 million through a series D round of financing. The funds would be used to initiate a phase I trial of XPro-1595 and conduct preclinical development of antibody therapeutics.

## R&D GRANTS

In October 2002, Xencor was awarded a $2 million advanced technology program grant from the National Institute of Standards and Technology to support the discovery of safer and more effective protein therapeutics. The3-year federal grant, titled "Rational Design of Non-immunogenic Proteins," would support the development of Xencor's ImmunoPDA technology to create new, non-immunogenic proteins optimized for therapeutic use and to eliminate immunogenicity from known protein drugs.

In June 2001, Xencor was awarded a $0.5 million SBIR phase II grant from the National Science Foundation. The grant would allow Xencor to further develop its enabling technology for computer directed high-throughput screening of proteins.

Return to Table of Contents

## PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Return to Table of Contents

Drugs by Indication Table

| Indication | Active | Inactive | Total |
|---|---|---|---|
| Neoplasm | 7 | 10 | 17 |
| Immune disorder | 5 | 8 | 13 |
| Hematological disease | 2 | 6 | 8 |
| Musculoskeletal disease | 1 | 4 | 5 |
| Inflammatory disease | 2 | 3 | 5 |
| Endocrine disease | 0 | 3 | 3 |
| Gynecology and obstetrics | 0 | 2 | 2 |
| Degeneration | 0 | 1 | 1 |
| Neurological disease | 0 | 1 | 1 |
| Genitourinary disease | 0 | 1 | 1 |
| Dermatological disease | 1 | 0 | 1 |
| Ocular disease | 0 | 1 | 1 |
| Metabolic disorder | 1 | 0 | 1 |
| Respiratory disease | 1 | 0 | 1 |

## Drugs by Highest Status

Active Drugs by Highest Status Chart




Return to Table of Contents

Drugs by Highest Status Table

| Development Status | Number of Drugs |
|---|---|
| Phase 2 Clinical | 1 |
| Phase 1 Clinical | 4 |
| Discovery | 6 |
| Discontinued | 4 |
| No Development Reported | 11 |

## DEALS

| Deal Type | Principal | | Partner | | Total |
|---|---|---|---|---|---|
| | Active | Inactive | Active | Inactive | |
| Drug - Discovery/Design | 1 | 0 | 1 | 0 | 2 |
| Technology - Other Proprietary | 11 | 0 | 1 | 0 | 12 |
| Patent - Non-Exclusive Rights | 1 | 0 | 0 | 0 | 1 |
| Drug - Funding | 2 | 0 | 0 | 0 | 2 |
| Drug - Screening/Evaluation | 1 | 0 | 0 | 0 | 1 |
| Drug - Early Research/Development | 2 | 0 | 0 | 0 | 2 |
| Drug - Development/Commercialization License | 3 | 0 | 0 | 0 | 3 |
| Drug - Manufacturing/Supply | 0 | 0 | 1 | 0 | 1 |
| Technology - Delivery/Formulation | 1 | 0 | 0 | 0 | 1 |
| Technology - Target Validation | 1 | 0 | 0 | 0 | 1 |

## CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---|---|---|
| Immune disorder | 0 | 5 |
| Inflammatory disease | 0 | 2 |
| Musculoskeletal disease | 0 | 2 |
| Neoplasm | 0 | 2 |
| Hematological disease | 0 | 2 |

Return to Table of Contents

### Trials by Phase

| Phase | Ongoing | All |
|---|---|---|
| Phase 2 | 0 | 2 |
| Phase 1 | 1 | 4 |

**Phase Definitions**

**Phase 3 Clinical**
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

**Phase 2 Clinical**
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

**Phase 1 Clinical**
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS *

| Indication | As Owner | As Third Party | Total |
|---|---|---|---|
| Cardiovascular disease | 10 | 0 | 10 |
| Endocrine disease | 10 | 0 | 10 |
| Gastrointestinal disease | 13 | 0 | 13 |
| Genitourinary disease | 2 | 0 | 2 |
| Growth disorder | 2 | 0 | 2 |
| Hematological disease | 12 | 0 | 12 |
| Degeneration | 2 | 0 | 2 |
| Immune disorder | 44 | 0 | 44 |
| Musculoskeletal disease | 19 | 0 | 19 |
| Neoplasm | 53 | 0 | 53 |
| Ocular disease | 2 | 0 | 2 |
| Genetic disorder | 2 | 0 | 2 |
| Metabolic disorder | 13 | 0 | 13 |
| Mouth disease | 4 | 0 | 4 |
| Neurological disease | 23 | 0 | 23 |
| Nutritional disorder | 2 | 0 | 2 |
| Respiratory disease | 6 | 0 | 6 |

Return to Table of Contents

| | | | |
|---|---|---|---|
| Infectious disease | 31 | 0 | 31 |
| Injury | 2 | 0 | 2 |
| Inflammatory disease | 34 | 0 | 34 |
| Otorhinolaryngological disease | 3 | 0 | 3 |
| Gynecology and obstetrics | 3 | 0 | 3 |
| Dermatological disease | 10 | 0 | 10 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE**: Highest status refers to highest development of that drug for one of the active companies

### XmAb-5871

| | |
|---|---|
| **Drug Name** | XmAb-5871 |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | Amgen Inc |
| **Highest Status** | Phase 2 Clinical |
| **Active Indications** | Rheumatoid arthritis, Systemic lupus erythematosus, Autoimmune disease |
| **Target-based Actions** | B-lymphocyte antigen CD19 inhibitor, Immunoglobulin gamma Fc receptor IIB antagonist |
| **Other Actions** | Immunomodulator, Anti-inflammatory |
| **Technologies** | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 11-Nov-2014 |

### omalizumab biosuperior, Xencor

| | |
|---|---|
| **Drug Name** | omalizumab biosuperior, Xencor |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Allergy, Asthma |
| **Target-based Actions** | Immunoglobulin gamma Fc receptor IIB modulator, Immunoglobulin E antagonist |
| **Other Actions** | Anti-inflammatory |
| **Technologies** | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant |
| **Last Change Date** | 11-Nov-2014 |

Return to Table of Contents

## anticancer monoclonal antibody (1), (Xmab), Boehringer

| | |
|---|---|
| **Drug Name** | anticancer monoclonal antibody (1), (Xmab), Boehringer |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc, Boehringer Ingelheim Corp |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Cancer |
| **Target-based Actions** | |
| **Other Actions** | Anticancer monoclonal antibody, Unspecified drug target |
| **Technologies** | Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 24-Sep-2013 |

## monoclonal antibody (2) (Xmab, cancer), Xencor/Boehringer Ingelheim

| | |
|---|---|
| **Drug Name** | monoclonal antibody (2) (Xmab, cancer), Xencor/Boehringer Ingelheim |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Boehringer Ingelheim Corp, Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Cancer |
| **Target-based Actions** | |
| **Other Actions** | Anticancer monoclonal antibody, Unspecified drug target |
| **Technologies** | Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 25-Sep-2013 |

Return to Table of Contents

## monoclonal antibody (autoimmune disease), Xencor/Merck

| | |
|---|---|
| **Drug Name** | monoclonal antibody (autoimmune disease), Xencor/Merck |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc, Merck & Co Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 1 Clinical |
| **Active Indications** | Autoimmune disease |
| **Target-based Actions** | |
| **Other Actions** | Immunomodulator, Unspecified drug target |
| **Technologies** | Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 13-Apr-2014 |

## cetuximab biosuperior, Xencor

| | |
|---|---|
| **Drug Name** | cetuximab biosuperior, Xencor |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Cancer |
| **Target-based Actions** | Epidermal growth factor ligand inhibitor |
| **Other Actions** | Anticancer monoclonal antibody |
| **Technologies** | Chimeric monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant |
| **Last Change Date** | 28-Sep-2012 |

Return to Table of Contents

## adalimumab biosuperior, Xencor

| | |
|---|---|
| **Drug Name** | adalimumab biosuperior, Xencor |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Autoimmune disease |
| **Target-based Actions** | TNF antagonist |
| **Other Actions** | Immunomodulator |
| **Technologies** | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 24-Sep-2013 |

## bevacizumab biosuperior, Xencor

| | |
|---|---|
| **Drug Name** | bevacizumab biosuperior, Xencor |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Solid tumor |
| **Target-based Actions** | VEGF ligand inhibitor |
| **Other Actions** | Anticancer monoclonal antibody |
| **Technologies** | Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant |
| **Last Change Date** | 28-Sep-2012 |

Return to Table of Contents

## bispecific antibody program (CD3 x CD38 target, cancer), Xencor Inc

| | |
|---|---|
| **Drug Name** | bispecific antibody program (CD3 x CD38 target, cancer), Xencor Inc |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Cancer |
| **Target-based Actions** | ADP ribosyl cyclase-1 modulator |
| **Other Actions** | CD3 modulator, Anticancer antibody |
| **Technologies** | Multivalent antibody, Biological therapeutic |
| **Last Change Date** | 11-Nov-2014 |

## XmAb-14045

| | |
|---|---|
| **Drug Name** | XmAb-14045 |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Acute myelogenous leukemia |
| **Target-based Actions** | CDw123 modulator |
| **Other Actions** | CD3 modulator, Anticancer antibody |
| **Technologies** | Multivalent antibody, Biological therapeutic |
| **Last Change Date** | 11-Nov-2014 |

Return to Table of Contents

## bispecific antibody program (CD3 x CD20 target, B-cell malignancies), Xencor Inc

| | |
|---|---|
| **Drug Name** | bispecific antibody program (CD3 x CD20 target, B-cell malignancies), Xencor Inc |
| **Key Synonyms** | |
| **Originator Company** | Xencor Inc |
| **Active Companies** | Xencor Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | B-cell lymphoma |
| **Target-based Actions** | B-lymphocyte antigen CD20 modulator |
| **Other Actions** | Anticancer antibody, CD3 modulator |
| **Technologies** | Multivalent antibody, Biological therapeutic, Parenteral formulation unspecified |
| **Last Change Date** | 08-Dec-2014 |

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.



Return to Table of Contents